Beth Rosenshein graduated from California State University, Long Beach in 1985 with a degree in Electrical and Bio-medical Engineering.
She has been awarded two United States Patents. One patent was awarded for a unique design of a vaginal speculum, suitable for use in the office and operating suite. Another patent was awarded for a clever urine collection device designed especially for women. She recently discovered and documented an important drug interaction between esomeprazole (Nexium™) and testosterone. Her findings were published in a case study in The American Journal of the Medical Sciences, May 2004. She successfully petitioned the FDA in September 2004 to change the labeling on hormone products.
Beth never set out to write a book on extending the functional life of the ovaries, but once her own ovarian function began to deteriorate she started doing her homework. After poring over thousands of medical studies, she concluded that extending ovarian function (preventing menopause) is logical, achievable, and absolutely safe. She consulted with doctors who agreed to work with her on a program for restoring actual ovarian hormone balance (not the balance achieved with HRT), and thus
significantly reversed the slide into hypogonadism (the medical term for
menopause) that was taking such a toll on her health
and her family life.

|